{"filings":[{"id":919122,"accession_number":"0001104659-26-071407","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2026-06-08T20:30:38+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia Corporation added to S&P SmallCap 600 Index effective June 22, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Index inclusion effective prior to open of trading on June 22, 2026.","S&P SmallCap 600 selects companies based on market cap, liquidity, public float, and profitability.","CEO Dr. Roger Jeffs called inclusion a meaningful marker of progress and team execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95779,"accession_number":"0001104659-26-058234","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUTREPIA net product sales $129.9M in Q1 2026; over 4,500 prescriptions, ~3,750 patients treated since June 2025 launch.","Net income $52.9M ($0.60 basic, $0.52 diluted) vs net loss $38.4M ($0.45 loss) in Q1 2025 – third consecutive profitable quarter.","Adjusted EBITDA $71.2M; cash & equivalents $222.8M, up $32.1M from Q4 2025.","R&D expenses $12.6M (+$5.6M YoY) driven by L606 and YUTREPIA clinical programs.","Screening PH-ILD patients for Phase 4 Tyvaso transition study and pivotal Phase 3 Re-Spire study of L606."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":132865000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109081,"accession_number":"0001104659-26-023794","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Liquidia posts Q4 net income $14.6M; YUTREPIA sales $90.1M in Q4, $148.3M FY2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $14.6M, positive non-GAAP adjusted EBITDA $27.3M; FY net loss $68.9M vs $128.3M in 2024.","YUTREPIA net product sales $148.3M in FY2025 ($90.1M Q4) since launch in June 2025; no product revenue in 2024.","Cash and equivalents $190.7M at Dec 31, 2025, up from $176.5M at Dec 31, 2024.","Over 3,600 prescriptions and 2,900 patients started since launch; prescribers ~860, 25% have referred 5+ patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109080,"accession_number":"0001104659-26-002306","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Liquidia reports preliminary 2025 YUTREPIA net sales of $148.3M; Q4 sales $90.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2025 YUTREPIA net sales ~$90.1M; full-year 2025 net sales ~$148.3M, up 74% QoQ.","Over 2,800 unique patient prescriptions since June 2025 launch; 85% conversion rate (Nov 2025).","Generated >$30M positive cash flow in Q4 2025; cash and equivalents ~$190.7M as of Dec 31.","Plan to expand field sales team in 2026; initiated multiple clinical studies for YUTREPIA and L606.","Preliminary results to be followed by audited full-year financials in Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125550,"accession_number":"0001104659-25-105199","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Liquidia Q3 2025: first YUTREPIA sales of $51.7M, achieves profitability, net loss narrows to $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of YUTREPIA $51.7M in first full quarter post-launch; operating income of $1.7M, positive adjusted EBITDA $10.1M.","Net loss narrowed to $3.5M ($0.04 loss per share) from $31.0M ($0.40 loss per share) in Q3 2024.","More than 2,000 unique patient prescriptions and 1,500 patient starts to date, supported by 600+ prescribers.","Cash and equivalents $157.5M at Sept 30, 2025; R&D down 21% to $9.3M; SG&A up 98% to $40.1M reflecting commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":66299000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125549,"accession_number":"0001104659-25-104000","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Liquidia licenses Vectura's nebulizer device for treprostinil L606 in US PAH/PH-ILD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment $2M; development milestones up to $12M; sales milestones up to $92.5M.","Royalties in mid-single digits; Vectura to manufacture and supply the device.","Exclusive US rights for treprostinil products treating hypertension and interstitial lung diseases (PAH, PH-ILD).","Rights of first negotiation for additional territories and indications during term.","Term until expiration of Royalty Term; termination for material breach, discontinuation, or patent challenge."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142289,"accession_number":"0001104659-25-076412","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Liquidia reports Q2 2025 results: YUTREPIA launch drives $6.5M product revenue, net loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUTREPIA (treprostinil) inhalation powder approved by FDA May 23, 2025; commercial launch in June 2025.","Over 900 unique patient prescriptions and 550 patient starts within 11 weeks post-approval.","ASCENT trial interim: median 6MWD improvement 31.5m at Week 16; median dose 159 mcg QID; no drug-related discontinuations.","Cash $173.4M as of June 30, 2025; product revenue $6.5M in Q2 2025 (first YUTREPIA sales).","Net loss $41.6M ($0.49 per share) vs $28.7M ($0.38) in Q2 2024; SG&A up 95% on commercialization and litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":11957000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142288,"accession_number":"0001104659-25-064738","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Liquidia appoints Dana Boyle as Chief Accounting Officer effective July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dana Boyle, previously SVP Finance and Controller, promoted to Chief Accounting Officer.","Annual base salary of $425,000; eligible for discretionary annual cash bonus of 50% of salary.","Granted RSUs valued at $300,000 under 2020 Long-Term Incentive Plan.","RSUs vest 25% on July 11, 2026, remainder quarterly over three years.","Eligible for severance benefits under Amended Executive Severance and Change in Control Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160306,"accession_number":"0001104659-25-061835","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia receives $50M from HCR after first commercial YUTREPIA sale and court win","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $50M from HCR after court denied preliminary injunction and first commercial sale of YUTREPIA.","Total funding under HCR agreement now $175M of $200M potential; $25M more available if net sales exceed $100M by June 30, 2026.","Payments to HCR capped at 175% of amounts funded; true-up due if IRR falls below 13% for this $50M tranche.","CFO says proceeds will accelerate launch execution, clinical pipeline, and manufacturing build-out."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160305,"accession_number":"0001104659-25-060654","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Liquidia shareholders elect three Class I directors, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Stephen Bloch (39.6M for), Joanna Horobin (45.4M), Roger Jeffs (46.1M) as Class I directors.","Ratified PricewaterhouseCoopers as auditor for FY 2025 with 67.5M for, 0.03M against.","Advisory say-on-pay vote passed with 44.4M for, 1.3M against, 0.5M abstain; 21.4M broker non-votes.","Quorum of 67.6M shares (79% of 85.4M outstanding) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160304,"accession_number":"0001104659-25-060649","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Liquidia leases 70,131 sq ft manufacturing facility at $260,069/mo base rent starting May 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for new manufacturing facility at 1000 Science Drive, Morrisville, NC; 70,131 rentable sq ft.","Term from June 16, 2025 to Nov 1, 2036; two 5-year renewal options.","Base rent $260,069.13/month starting May 1, 2026, increasing 3% annually; first six months rent abated.","One-time right of first offer on contiguous space in the Building when available.","Landlord is King Combs LLC; Liquidia Technologies, Inc. is tenant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160303,"accession_number":"0001104659-25-055180","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia starts YUTREPIA shipments after FDA approval; court denies UTHR injunction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First commercial shipment of YUTREPIA (treprostinil) inhalation powder to specialty pharmacies scheduled.","FDA approved YUTREPIA on May 23, 2025 for PAH and PH-ILD.","Court denied United Therapeutics' motion for preliminary injunction and TRO on May 30, 2025.","Court concluded UTHR unlikely to succeed on merits; Liquidia's motion to dismiss remains pending.","CEO cites rapid launch: sales force active, product listed with compendia within one week."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160302,"accession_number":"0001104659-25-052454","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Liquidia's YUTREPIA for PAH and PH-ILD, enabling commercial launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved YUTREPIA (treprostinil) inhalation powder for PAH and PH-ILD to improve exercise ability.","Exclusivity for United Therapeutics' Tyvaso DPI expired May 23, 2025, clearing path for YUTREPIA final approval.","YUTREPIA uses proprietary PRINT technology for deep-lung delivery; pivotal INSPIRE study showed tolerability.","Liquidia intends to begin commercialization immediately; ongoing litigation may delay or prevent successful commercialization.","Company will host a webcast May 27, 2025 at 8:30 a.m. ET to discuss commercial launch preparations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160301,"accession_number":"0001104659-25-046935","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"UTHR files patent suit against Liquidia seeking to block YUTREPIA commercialization","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["UTHR sued Liquidia on May 9, 2025 alleging infringement of the '782 patent and seeking an injunction against YUTREPIA launch if FDA-approved.","UTHR is not seeking an injunction against the FDA; PDUFA goal date for YUTREPIA remains May 24, 2025.","The '782 patent is from the same family as the '793 patent, which was invalidated by the PTAB and upheld through appeals.","Liquidia CEO states they expect to invalidate these claims as done previously with the '793 patent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160300,"accession_number":"0001558370-25-006838","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia corrects immaterial accounting errors in HCR debt amendments; revises 2024 financials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reclassified HCR amendments from extinguishment to modification, eliminating gain/loss and adjusting interest expense.","Revised FY2024 annual and Q1-Q3 2024 interim financial statements; errors deemed immaterial.","Auditor PwC issued revised opinion with going-concern emphasis; internal controls remain effective.","Company continues to face substantial doubt about ability to continue as going concern.","Voluntary correction filed via 8-K on May 8, 2025, for the year ended December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160299,"accession_number":"0001104659-25-045850","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Liquidia Q1 net loss $38.4M ($0.45/sh); PDUFA May 24; court dismisses UTHR cross-claim","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $38.4M ($0.45 per share) vs $30.1M ($0.40) prior year; cash $169.8M.","Revenue $3.1M from Sandoz promotion agreement; R&D down 31% as shift to commercialization.","PDUFA goal date May 24, 2025 for YUTREPIA NDA; FDA accepted Class 1 resubmission.","District Court dismissed UTHR cross-claim challenging PH-ILD amendment; UTHR may appeal.","Amended HCR agreement provides up to $100M additional financing for commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":3120000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160298,"accession_number":"0001104659-25-044345","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia wins dismissal of UTHR cross-claim over YUTREPIA PH-ILD label; FDA approval path cleared","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["District Court dismissed UTHR's cross-claim without prejudice for lack of standing and ripeness.","FDA can grant final YUTREPIA approval after regulatory exclusivity expires on May 23, 2025.","PDUFA goal date for YUTREPIA NDA remains May 24, 2025.","UTHR retains the right to appeal the court's ruling.","CEO cites court decision as validating FDA's acceptance of PH-ILD indication in NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160297,"accession_number":"0001104659-25-037137","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia files patent infringement suit against United Therapeutics over treprostinil dry powder patent","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed lawsuit on April 21, 2025 in the Middle District of North Carolina against United Therapeutics.","Alleges infringement of U.S. Patent No. 10,898,494 covering dry powder treprostinil for pulmonary hypertension.","Action filed by Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation.","Patent infringement claim seeks remedy for unauthorized use of Liquidia's dry powder treprostinil technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178592,"accession_number":"0001104659-25-029401","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia's YUTREPIA NDA resubmission accepted; PDUFA date May 24, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted Liquidia's NDA resubmission for YUTREPIA (treprostinil) inhalation powder.","Resubmission is a complete, Class 1 response to the August 16, 2024 action letter.","FDA granted tentative approval for PAH and PH-ILD; final approval decision by May 24, 2025.","Company preparing for launch of YUTREPIA pending final FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178591,"accession_number":"0001104659-25-025326","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Liquidia targets final YUTREPIA approval May 23, 2025; FY 2024 net loss $130.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 revenue $14.0M (down from $17.5M) driven by Treprostinil Injection promotion; net loss $130.4M ($1.66/share) vs $78.5M loss prior year.","FDA tentative approval of YUTREPIA (PAH/PH-ILD) granted Aug 2024; final approval expected after NCI exclusivity expires May 23, 2025.","HCRx financing amended for up to $100M: $25M received at closing, $50M contingent on first YUTREPIA sale, $25M upon $100M net sales milestone.","Cash and equivalents $176.5M at Dec 31, 2024, up from $83.7M a year earlier.","ASCENT study (YUTREPIA in PH-ILD) nearing enrollment completion; L606 (liposomal treprostinil) U.S. open-label study ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178590,"accession_number":"0001104659-25-024784","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Liquidia secures up to $100M in additional financing from HCR for YUTREPIA commercialization","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$25M funded at closing; $50M contingent on first commercial sale of YUTREPIA after FDA approval for PAH/PH-ILD (no injunction).","Additional $25M available if YUTREPIA net sales exceed $100M by June 30, 2026, subject to mutual agreement.","Payments capped at 175% of amounts advanced; minimum IRR rates: 16%/13%/12% for three new tranches.","CFO: combination of proceeds and successful YUTREPIA launch could lead to profitability without additional capital.","Proceeds to fund YUTREPIA commercial development, clinical trials, L606 development, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178589,"accession_number":"0001104659-25-018635","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia loses court challenge to FDA's Tyvaso DPI exclusivity; cross claim still pending","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On Feb 27, 2025, District Court denied Liquidia's summary judgment motion, affirming FDA's 3-year exclusivity for Tyvaso DPI.","Exclusivity expiration remains May 23, 2025; decision does not change that date.","United Therapeutics' cross claim challenging FDA's acceptance of Liquidia's amended NDA remains pending; dismissal motions not yet ruled on.","Liquidia filed lawsuit in August 2024; this ruling is a legal setback for their NDA approval timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195259,"accession_number":"0001104659-24-123155","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Liquidia extends headquarters lease through 2031 with escalating base rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease extended 62 months from Nov 2026 to Dec 2031; first two months' base rent abated.","Monthly base rent starts at $136,224.48 and increases to $157,907.66 in final two months.","Tenant retains one five-year renewal option and a one-time right of first offer on vacant space.","Amendments retroactively convert operating expenses to triple-net basis; insurance and hazardous substance clauses updated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195258,"accession_number":"0001104659-24-117193","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Liquidia Q3 net loss $23.2M; FDA tentative approval for YUTREPIA; raised $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.2M ($0.30/diluted share) vs $15.8M loss a year ago; revenue $4.4M from Treprostinil injection promotion.","Cash $204.4M as of Sep 30, 2024, boosted by $67.5M public offering and $32.5M from HCRx RIFA amendment.","FDA granted tentative approval for YUTREPIA (treprostinil inhalation powder) for PAH and PH-ILD; final approval delayed until May 23, 2025.","Supreme Court rejected UTHR appeal on '793 patent; remaining '327 patent trial set for June 2025; Liquidia sued FDA over exclusivity.","Expanded Pharmosa collaboration for L606 to Europe, Japan; $3.5M upfront, up to $157.75M milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":11079000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195257,"accession_number":"0001104659-24-106685","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supreme Court denies United Therapeutics' certiorari; Liquidia's '793 patent invalid final","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Supreme Court rejected UTHR's cert petition, finalizing PTAB and Federal Circuit rulings that all claims of U.S. Patent No. 10,716,793 are invalid.","No valid claims of the three patents originally asserted by UTHR found infringed; all decisions final and not subject to further appeal.","FDA granted tentative approval of YUTREPIA for PAH and PH-ILD on Aug 16, 2024; final approval may occur after May 23, 2025.","U.S. District Court denied UTHR's preliminary injunction on '327 patent; trial scheduled for June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195256,"accession_number":"0001104659-24-105182","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Liquidia expands L606 license to Europe/Japan; gets nebulizer rights; $3.5M upfront, up to $157.75M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expanded exclusive license to include Europe, Japan, and other key markets outside North America; $3.5M upfront payment.","Up to $157.75M in additional milestone payments: $7.75M development + $150M commercial sales milestones outside North America.","Obtained exclusive rights to Pharmosa's next-generation smart-technology nebulizers for use with L606.","L606 pivotal study in PH-ILD expected to start later this year; positive EMA scientific advice received.","Open-label safety study shows L606 tolerated up to 378 mcg twice daily; supports twice-daily dosing via breath-actuated nebulizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211516,"accession_number":"0001104659-24-100714","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Therapeutics files new cross-claims in FDA suit challenging YUTREPIA NDA acceptance","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On Sept. 16, 2024, United Therapeutics filed new cross-claims against FDA in the existing FDA Suit.","Cross-claims re-assert challenge to FDA's acceptance of Liquidia's NDA for YUTREPIA (treprostinil).","Liquidia states it will vigorously defend its ability to launch YUTREPIA and against the allegations.","United had voluntarily dismissed a similar challenge on Aug. 20, 2024, before refiling as cross-claims.","Liquidia's prior suit challenging FDA's 3-year NCI exclusivity for Tyvaso DPI remains ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211515,"accession_number":"0001104659-24-099305","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Liquidia raises $67.5M in equity and activates $32.5M debt facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 1,123,595 shares at $8.90/share to Caligan Partners LP (fund controlled by director David Johnson) for $10M.","Underwritten public offering of 6,460,674 shares at $8.90/share for gross proceeds of $57.5M.","Fifth Amendment to RIFA with HealthCare Royalty Partners provides $32.5M additional funding; condition satisfied by equity raises.","All transactions closed on September 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211514,"accession_number":"0001104659-24-098792","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Liquidia raises ~$100M from stock offerings and RIFA advance for YUTREPIA development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 6,460,674 shares at $8.90/share for ~$57.5M gross; private placement of 1,123,595 shares at $8.90/share for $10M.","Fifth Amendment to RIFA with HCR provides additional $32.5M, bringing total RIFA to $100M; funding condition met upon stock offering close.","Modified fixed payment schedule extends RIFA termination from 2029 to 2031; $23.8M payment deferred to 2026.","Proceeds to fund YUTREPIA commercial development, pediatric/WHO Group 1/3 trials, and L606 clinical development.","BofA Securities sole bookrunner; fund affiliated with Paul Manning invested ~$3M in offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211513,"accession_number":"0001104659-24-098781","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Liquidia amends financing with HCR, extends payments to 2031, adds $32.5M subject to equity raise","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fifth Amendment moves remaining $32.5M from tranches 3/4 to tranche 2; total $100M non-dilutive capital fully committed.","Payment schedule extended from 2029 to 2031; $23.8M payment due July 2025 deferred to two equal payments in Jan and July 2026.","Funding of $32.5M conditioned on Liquidia raising at least $50M in gross proceeds from common stock sales on or after Sept 11, 2024.","Aggregate payments capped at 175% of funded amounts; true-up threshold lowered to 16% for new funds (vs 18% prior)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211512,"accession_number":"0001104659-24-091806","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia sues FDA over Tyvaso DPI exclusivity blocking YUTREPIA approval","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["FDA granted tentative approval of YUTREPIA on Aug 16, 2024, but final approval delayed until after May 23, 2025.","Liquidia filed suit in D.C. District Court (Case No. 1:24-cv-02428) challenging FDA's 3-year NCI exclusivity for Tyvaso DPI.","United Therapeutics voluntarily dismissed its complaint challenging FDA's acceptance of Liquidia's amended NDA on Aug 20.","Liquidia argues FDA's decision violates congressional intent and seeks to vacate exclusivity to allow timely market entry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211511,"accession_number":"0001104659-24-090676","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants tentative approval for Liquidia's YUTREPIA but final approval delayed to May 2025 due to exclusivity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted tentative approval of YUTREPIA (treprostinil) inhalation powder for PAH and PH-ILD on Aug 19, 2024.","Final approval delayed until after expiration of Tyvaso DPI's three-year new dosage form exclusivity on May 23, 2025.","Liquidia plans to challenge FDA's broad grant of regulatory exclusivity to United Therapeutics for Tyvaso DPI.","Tentative approval confirms YUTREPIA meets FDA standards for quality, safety, and efficacy but cannot be marketed yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211510,"accession_number":"0001104659-24-086529","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Liquidia Q2 net loss $27.9M; court rulings clear legal path for YUTREPIA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $27.9M ($0.37/share) vs $23.5M ($0.36/share) in Q2 2023.","Revenue from Sandoz promotion $3.7M, down from $4.8M due to lower sales volumes.","Cash and equivalents $133.1M at June 30, 2024, up from $83.7M at Dec 31, 2023.","Court denied UTHR's preliminary injunction on YUTREPIA patent '327 on May 31; D.C. court also denied TRO/PI against FDA.","R&D expense fell 47% to $9.4M (no prior-year license fee); G&A rose 116% to $20.0M on sales force and legal costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":6631000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230188,"accession_number":"0001104659-24-073965","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Liquidia shareholders approve increase in authorized shares to 115M at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class III directors Damian deGoa, Arthur Kirsch, Paul B. Manning for terms until 2027.","Approved charter amendment raising authorized common stock from 100M to 115M shares.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year 2024.","Advisory vote approved compensation of named executive officers.","Advisory vote selected one-year frequency for future say-on-pay votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230187,"accession_number":"0001104659-24-067453","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia wins denial of United Therapeutics' preliminary injunction blocking YUTREPIA launch","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On May 31, Judge Andrews denied UTHR's motion for a preliminary injunction to block launch of YUTREPIA for PH-ILD.","Court found UTHR failed to show obviousness challenge lacked merit and public interest did not favor an injunction.","Ruling maintains no legal impediment to FDA granting final approval of YUTREPIA for PAH and PH-ILD; trial set for June 2025.","Earlier rulings: PTAB and Federal Circuit found YUTREPIA does not infringe other UTHR patents; UTHR plans Supreme Court appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230186,"accession_number":"0001104659-24-067273","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Therapeutics sues Liquidia and ex-employee over YUTREPIA IP misappropriation","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Complaint filed May 29, 2024 in Durham County, NC, against former employee and Liquidia subsidiary.","Alleges breach of employment agreements and misappropriation of IP leading to YUTREPIA (treprostinil) inhalation powder.","United Therapeutics seeks assignment of patents and declaratory relief that inventions belong to them.","Liquidia intends to vigorously defend against the allegations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230185,"accession_number":"0001104659-24-061188","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Liquidia amends executive severance plan with tiered benefits up to 24 months base salary plus incentive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amended Executive Severance Plan effective May 9, 2024; supersedes prior plans and employment agreements.","Tier 1 participants receive up to 18 months base salary (non-CIC) or 24 months base salary plus target annual incentive (CIC).","Tier 2-4 participants receive 6-12 months base salary depending on tier; CIC termination triggers full equity vesting for all participants.","COBRA premium coverage provided for 6-24 months based on tier and event type.","Plan defines four participation tiers; administration by Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230184,"accession_number":"0001104659-24-060715","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Liquidia Q1 net loss widens to $40.9M; YUTREPIA legal barriers removed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.9M ($0.54/share) vs $11.7M ($0.18) in Q1 2023; revenue fell 33% to $3.0M on lower Treprostinil Injection sales.","Cash $157.9M after $100M gross proceeds from common stock private placement and RIFA fourth amendment in January 2024.","G&A expenses surged 160% to $20.2M, driven by $3.1M higher litigation costs and $5.9M personnel rise.","All legal barriers to FDA approval of YUTREPIA removed; awaiting ruling on preliminary injunction in new UTHR patent suit.","ASCENT study of YUTREPIA in PH-ILD enrolling; L606 liposomal treprostinil data to be presented at ATS 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":2972000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230183,"accession_number":"0001104659-24-041462","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Judge lifts YUTREPIA injunction; Tyvaso PH-ILD exclusivity expires March 31","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["March 28: Judge Andrews set aside August 2022 injunction; FDA can now approve YUTREPIA NDA.","March 29: Judge Bates denied United Therapeutics' motion for TRO/preliminary injunction against FDA approval.","March 31: Regulatory exclusivity for Tyvaso in PH-ILD expired; FDA can act on YUTREPIA amended NDA.","United Therapeutics filed appeal and new lawsuits, but none currently block YUTREPIA launch.","Liquidia commercial team ready to launch for PAH and PH-ILD upon FDA final approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248615,"accession_number":"0001104659-24-033684","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Liquidia FY2023 net loss $78.5M ($1.21/sh); patent victory clears path for YUTREPIA launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $78.5M ($1.21/sh) vs $41.0M ($0.67/sh) in FY2022; R&D spend rose 122% to $43.2M.","Cash $83.7M at Dec 31, 2023; raised $100M in Jan 2024 via equity placement and debt amendment.","Federal Circuit denied United Therapeutics' rehearing request, upholding invalidity of '793 Patent; injunction removal awaited.","YUTREPIA ready for launch in PAH and PH-ILD after Tyvaso exclusivity expires March 31, 2024 and injunction lifted.","L606 Phase 3 PH-ILD study planned by end-2024; ASCENT enrollment (60 patients) ongoing with interim data expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248614,"accession_number":"0001104659-24-006477","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA delays YUTREPIA PDUFA date; PH-ILD amendment process ongoing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA unable to issue action letter by Jan. 24, 2024 PDUFA date; no new goal date set.","No additional clinical data requested; FDA confirming process to add PH-ILD indication.","Federal Circuit upheld PTAB invalidity of '793 patent; '327 patent not subject to 30-month stay.","Company expects final approval after Tyvaso regulatory exclusivity expires March 31, 2024.","YUTREPIA already has tentative approval for PAH; quality, safety, efficacy standards met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248613,"accession_number":"0001104659-24-005743","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Liquidia: United Therapeutics dismisses '793 Patent claims in PH-ILD litigation; '327 Patent remains","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On Jan 22, 2024, United Therapeutics stipulated to dismiss all claims related to the '793 Patent in the New Hatch-Waxman Litigation.","Only claims related to the '327 Patent remain; Liquidia asserts the '327 Patent does not entitle a 30-month regulatory stay.","The dismissal does not affect the injunction issued in the Original Hatch-Waxman Litigation (filed June 2020).","Liquidia's motion to set aside the original injunction is fully briefed; awaiting the District Court's decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248612,"accession_number":"0001104659-24-005009","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Liquidia terminates COO Lippe, promotes CFO Kaseta to COO/CFO, grants 50K RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Lippe terminated as COO on Jan 15, 2024; will remain at-will through Apr 15, 2024.","Michael Kaseta (CFO) promoted to COO effective Jan 15; base salary increased to $575,000.","Kaseta received 50,000 restricted stock units under the 2020 Long-Term Incentive Plan.","Michael Hunter promoted to SVP of Manufacturing Operations as part of restructuring.","Changes come ahead of potential YUTREPIA (treprostinil) approval and commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248611,"accession_number":"0001104659-24-002247","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Liquidia closes $75M PIPE, draws $25M debt facility, files counterclaims in UTHR patent suit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 7.18M shares at $10.442/share for ~$75M gross proceeds; additional $25M drawn under revenue interest financing amendment.","Filed response to UTHR patent suit seeking dismissal of invalidated '793 patent claims and asserting counterclaims that '327 patent is invalid due to undisclosed prior art.","Enrolled first PH-ILD patient in YUTREPIA ASCENT study; PDUFA date for tentative approval is Jan 24, 2024.","FDA agreed that single Phase 3 trial of L606 in PH-ILD will support both PAH and PH-ILD indications; global study to start later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248610,"accession_number":"0001104659-24-001504","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Liquidia raises $100M: $75M equity private placement + $25M debt from HCR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 7,182,532 shares at $10.442/share (8% discount to Jan 3 close) to Patient Square Capital affiliate; gross proceeds ~$75M.","Fourth amendment to RIFA funds additional $25M from HCR, bringing total drawn to $67.5M; remaining $32.5M available upon mutual agreement.","CFO says combined $126M (including Dec 2023 offerings) positions company to reach profitability if YUTREPIA launches by April 2024.","Proceeds to fund commercial development, clinical trials for YUTREPIA (PAH/PH-ILD) and L606, plus general corporate purposes.","Equity issuance expected to close January 8, 2024; no broker fees paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266113,"accession_number":"0001104659-23-127783","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia wins Federal Circuit ruling affirming invalidation of United Therapeutics' '793 patent","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Federal Circuit upheld PTAB decision finding all claims of U.S. Patent No. 10,716,793 unpatentable.","Liquidia will immediately seek to set aside the District Court injunction and pursue final FDA approval of YUTREPIA.","FDA PDUFA goal date for PH-ILD indication is January 24, 2024.","CEO Roger Jeffs stated company now has rulings that YUTREPIA does not infringe any valid claim in three initially asserted patents.","Liquidia will also seek dismissal of related claims in second Hatch-Waxman lawsuit and defend against new '327 patent allegations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266112,"accession_number":"0001104659-23-126023","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Liquidia closes $26M equity raises: public offering $25M, CEO private placement $1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed public offering of 3,491,620 shares at $7.16 for gross proceeds of approx. $25M.","Closed private placement to CEO Roger Jeffs of 139,665 shares at $7.16 for $1M.","Both transactions closed on Dec. 14, 2023; shares issued at $7.16 per share.","Private shares are restricted securities exempt from registration under Section 4(a)(2).","Offering structured as underwritten public offering with BofA Securities as representative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266111,"accession_number":"0001104659-23-125203","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Liquidia prices $25M public offering at $7.16/share; CEO invests $1M in concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,491,620 shares priced at $7.16 in underwritten public offering; gross proceeds ~$25M.","Funds to support YUTREPIA commercial development, clinical trials (WHO Group 3, pediatric), and L606 development.","CEO Roger Jeffs invests ~$1M in parallel private placement of 139,665 shares at same price.","BofA Securities sole book-runner, BTIG lead manager; expected close Dec 14, 2023.","Directors Johnson and Manning participate with $10M aggregate investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266110,"accession_number":"0001104659-23-125170","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liquidia faces new PH-ILD patent infringement suit from United Therapeutics on '327 Patent","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["United Therapeutics filed amended complaint Nov 30, 2023, alleging YUTREPIA infringes new '327 Patent covering inhaled treprostinil for PH-ILD.","The '327 Patent issued Nov 28, 2023; Liquidia argues no 30-month stay because it issued after original NDA filing.","Ongoing IPR of '793 Patent: PTAB ruled claims unpatentable; appeal pending at Federal Circuit after Dec 4, 2023 oral argument.","Liquidia intends to vigorously defend; previous Hatch-Waxman ruling still blocks YUTREPIA approval for PH-ILD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266109,"accession_number":"0001104659-23-122617","cik":1819576,"company_name":"Liquidia Corp","ticker":"LQDA","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Liquidia faces new patent infringement claim over '327 patent added to PH-ILD suit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["United Therapeutics amended complaint adds U.S. Patent No. 11,826,327, issued Nov 28, 2023.","Patent covers inhaled treprostinil for PH-ILD; YUTREPIA label amendment triggers claim.","Liquidia believes no 30-month stay applies because patent issued after original NDA filing.","Case continues in U.S. District Court for Delaware; Liquidia vows vigorous defense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5475303288.234583,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-12-01T23:59:59+00:00|266109"}